Dr. Weber joined Domain in 2001 as a partner, where he specializes in creating companies around promising new pharmaceutical products. He has been the founding CEO of multiple biopharmaceutical companies in the Domain portfolio, including Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia, Domain Antibacterial Acquisition Corporation, NovaCardia, Novacea, Novalar Pharmaceuticals, Ocera Therapeutics, Orexigen Therapeutics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics, and Tragara Pharmaceuticals. He currently serves as interim CEO of Calixa Therapeutics and Sonexa Therapeutics, two seed-stage biopharmaceutical companies. He is Chairman of the Board at Ascenta Therapeutics, Ocera Therapeutics, Orexigen Therapeutics, Sequel Pharmaceuticals, Syndax Pharmaceuticals, and Tobira Therapeutics. He was Chairman of Peninsula Pharmaceuticals until the company was sold to Johnson & Johnson in 2005, Chairman of Cerexa until the company was sold to Forest Laboratories in January 2007, Chairman of NovaCardia until the company was sold to Merck in September 2007, and a board member of Conforma Therapeutics and Cabrellis Pharmaceuticals until they were sold to Biogen-IDEC and Pharmion, respectively. In addition, he is a board member of BioVascular and DiObex. Until 1995, Mr. Weber was a tenured Professor of Pharmacology at the University of California at Irvine. He has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. He is the inventor or co-inventor of over 40 patents and patent applications, and he has published over 130 papers in scientific journals.